在治疗寻常型牛皮癣患者期间，从guelkumab成功切换到tildrakizumab

IF 1.1 Q4 ALLERGY

Journal of Cutaneous Immunology and Allergy Pub Date : 2022-10-19 DOI:10.1002/cia2.12284

Kazuki Yatsuzuka MD, Masamoto Murakami MD, PhD

{"title":"在治疗寻常型牛皮癣患者期间，从guelkumab成功切换到tildrakizumab","authors":"Kazuki Yatsuzuka MD, Masamoto Murakami MD, PhD","doi":"10.1002/cia2.12284","DOIUrl":null,"url":null,"abstract":"<p>This was the first case report in which an in-class IL-23 p19 inhibitor was switched (from guselkumab to tildrakizumab) during psoriasis vulgaris treatment. Four months after the switch, genital lesions, which were the patient's most significant complaint, improved with no subsequent worsening. We believe that our case will aid physicians who work in this problematic clinical setting.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2022-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12284","citationCount":"1","resultStr":"{\"title\":\"A successful switch from guselkumab to tildrakizumab during the treatment of a patient with psoriasis vulgaris\",\"authors\":\"Kazuki Yatsuzuka MD, Masamoto Murakami MD, PhD\",\"doi\":\"10.1002/cia2.12284\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>This was the first case report in which an in-class IL-23 p19 inhibitor was switched (from guselkumab to tildrakizumab) during psoriasis vulgaris treatment. Four months after the switch, genital lesions, which were the patient's most significant complaint, improved with no subsequent worsening. We believe that our case will aid physicians who work in this problematic clinical setting.\\n <figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure></p>\",\"PeriodicalId\":15543,\"journal\":{\"name\":\"Journal of Cutaneous Immunology and Allergy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2022-10-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12284\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cutaneous Immunology and Allergy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cia2.12284\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cutaneous Immunology and Allergy","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cia2.12284","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 1

摘要

寻常型银屑病（PSV）有多种治疗选择；在生物制剂方面，日本有10多种药物，包括肿瘤坏死因子（TNF）α抑制剂、白细胞介素（IL）17抑制剂、IL12/23p40抑制剂和IL23p19抑制剂。如果上述药物类别中的一种不能显著改善银屑病皮肤病变，我们通常会改用另一类药物。然而，我们也进行“包含”切换，例如，从一种IL17A抑制剂切换到另一种。1由于IL23 p19抑制剂相对较新，因此包含切换功效的证据有限。我们报道了银屑病患者首次成功地从古斯库单抗转为替拉基单抗。一名有10年PSV病史的35岁男子全身出现鳞状和红斑斑块。他的体重指数为30 kg/m2。皮肤损伤对局部皮质类固醇、免疫抑制剂、阿普司特和ustekinumab是难治性的。由于他不愿意使用自动注射器，我们给他开了古斯库单抗（每8周100毫克）；这使他的银屑病面积和严重程度指数得分从11.3提高到2.4。然而，只剩下头皮和生殖器损伤。在开始使用古斯库单抗两年后，患者的皮肤病生活质量指数（DLQI）评分为6，主要是因为生殖器病变。此外，他负担不起每8周一次的治疗费用。因此，我们改用替拉单抗（初始给药后每12周100 mg

本文章由计算机程序翻译，如有差异，请以英文原文为准。

A successful switch from guselkumab to tildrakizumab during the treatment of a patient with psoriasis vulgaris

查看原文本刊更多论文

A successful switch from guselkumab to tildrakizumab during the treatment of a patient with psoriasis vulgaris

This was the first case report in which an in-class IL-23 p19 inhibitor was switched (from guselkumab to tildrakizumab) during psoriasis vulgaris treatment. Four months after the switch, genital lesions, which were the patient's most significant complaint, improved with no subsequent worsening. We believe that our case will aid physicians who work in this problematic clinical setting.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Cutaneous Immunology and Allergy Medicine-Dermatology

CiteScore

0.60

自引率

10.00%

发文量

审稿时长

12 weeks